Barbara Alsen Degar, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphohistiocytosis, Hemophagocytic | 10 | 2022 | 264 | 1.930 |
Why?
|
Histiocytosis, Langerhans-Cell | 9 | 2024 | 169 | 1.180 |
Why?
|
Hodgkin Disease | 1 | 2023 | 1377 | 0.520 |
Why?
|
Cytarabine | 3 | 2024 | 696 | 0.420 |
Why?
|
Etoposide | 3 | 2023 | 630 | 0.370 |
Why?
|
Xanthogranuloma, Juvenile | 2 | 2024 | 16 | 0.370 |
Why?
|
Leukemia, Myeloid, Acute | 7 | 2024 | 3599 | 0.370 |
Why?
|
Macrophage Activation Syndrome | 2 | 2022 | 123 | 0.340 |
Why?
|
Torque teno virus | 1 | 2024 | 13 | 0.230 |
Why?
|
Receptors, Amino Acid | 1 | 2024 | 30 | 0.230 |
Why?
|
Organophosphorus Compounds | 1 | 2023 | 203 | 0.210 |
Why?
|
Pyrazoles | 2 | 2024 | 1990 | 0.210 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2024 | 251 | 0.200 |
Why?
|
Leukemoid Reaction | 1 | 2022 | 18 | 0.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11709 | 0.190 |
Why?
|
Child | 25 | 2024 | 79813 | 0.180 |
Why?
|
Pyrimidines | 2 | 2024 | 3006 | 0.180 |
Why?
|
Child, Preschool | 19 | 2024 | 42058 | 0.150 |
Why?
|
Isotretinoin | 1 | 1999 | 132 | 0.150 |
Why?
|
Anthracyclines | 1 | 2019 | 282 | 0.140 |
Why?
|
Nitriles | 1 | 2022 | 957 | 0.140 |
Why?
|
Homeodomain Proteins | 2 | 2006 | 2413 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1594 | 0.130 |
Why?
|
GATA2 Transcription Factor | 1 | 2016 | 158 | 0.130 |
Why?
|
Bone Marrow | 4 | 2014 | 2909 | 0.130 |
Why?
|
Central Nervous System Diseases | 1 | 2019 | 520 | 0.120 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 223 | 0.120 |
Why?
|
Eosinophilia | 1 | 1999 | 559 | 0.120 |
Why?
|
Haploinsufficiency | 1 | 2016 | 327 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2022 | 2004 | 0.110 |
Why?
|
Down Syndrome | 1 | 2022 | 892 | 0.110 |
Why?
|
Community Health Nursing | 1 | 2013 | 23 | 0.110 |
Why?
|
Infant | 13 | 2024 | 36054 | 0.110 |
Why?
|
Neoplasm, Residual | 3 | 2014 | 1007 | 0.110 |
Why?
|
Home Nursing | 1 | 2013 | 92 | 0.110 |
Why?
|
Interferon-gamma | 1 | 2020 | 3156 | 0.100 |
Why?
|
Bone Diseases | 1 | 2015 | 419 | 0.100 |
Why?
|
Killer Cells, Natural | 2 | 2019 | 2201 | 0.090 |
Why?
|
Inflammation | 2 | 2019 | 10719 | 0.090 |
Why?
|
Bone Marrow Transplantation | 1 | 1999 | 2693 | 0.090 |
Why?
|
Leukemia | 1 | 2019 | 1519 | 0.090 |
Why?
|
Neuroblastoma | 1 | 1999 | 1251 | 0.090 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 1931 | 0.090 |
Why?
|
Pharmacogenetics | 2 | 2024 | 675 | 0.090 |
Why?
|
Enterovirus Infections | 1 | 2010 | 74 | 0.090 |
Why?
|
Meningoencephalitis | 1 | 2010 | 83 | 0.090 |
Why?
|
Humans | 40 | 2024 | 758381 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 1 | 2001 | 3384 | 0.080 |
Why?
|
Diagnosis, Differential | 5 | 2019 | 12951 | 0.070 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 164 | 0.070 |
Why?
|
Infant, Newborn | 7 | 2022 | 26182 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2001 | 5787 | 0.070 |
Why?
|
Neurodegenerative Diseases | 1 | 2015 | 1081 | 0.070 |
Why?
|
Skin Diseases | 1 | 2014 | 1088 | 0.070 |
Why?
|
Transcription Factors | 2 | 2006 | 12096 | 0.060 |
Why?
|
Adolescent | 13 | 2024 | 87888 | 0.060 |
Why?
|
Remission Induction | 3 | 2019 | 2388 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2023 | 80170 | 0.060 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 2004 | 22 | 0.060 |
Why?
|
Receptor, Notch1 | 1 | 2008 | 495 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2020 | 9160 | 0.060 |
Why?
|
Hematopoiesis | 2 | 2006 | 2047 | 0.060 |
Why?
|
Disease-Free Survival | 4 | 2019 | 6821 | 0.060 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2020 | 5649 | 0.060 |
Why?
|
Female | 24 | 2024 | 390316 | 0.060 |
Why?
|
Neoplasms | 4 | 2024 | 22030 | 0.050 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 8530 | 0.050 |
Why?
|
Male | 21 | 2024 | 358742 | 0.050 |
Why?
|
Liver Transplantation | 1 | 2014 | 2325 | 0.050 |
Why?
|
Incidence | 3 | 2015 | 21273 | 0.050 |
Why?
|
Graft vs Host Disease | 1 | 2014 | 3024 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2004 | 629 | 0.050 |
Why?
|
Brain | 2 | 2019 | 26951 | 0.050 |
Why?
|
Genetic Techniques | 1 | 2004 | 427 | 0.050 |
Why?
|
Medication Adherence | 1 | 2013 | 2155 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2004 | 886 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 17768 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2024 | 3615 | 0.050 |
Why?
|
Paired Box Transcription Factors | 1 | 2001 | 206 | 0.050 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2024 | 638 | 0.040 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2010 | 2053 | 0.040 |
Why?
|
Vidarabine | 2 | 2019 | 336 | 0.040 |
Why?
|
Chemokine CXCL9 | 1 | 2020 | 135 | 0.040 |
Why?
|
Genetic Variation | 1 | 2015 | 6548 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2019 | 5797 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2024 | 64379 | 0.040 |
Why?
|
Antineoplastic Agents | 2 | 1999 | 13591 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4839 | 0.040 |
Why?
|
Gastrointestinal Diseases | 1 | 2006 | 1185 | 0.040 |
Why?
|
Receptors, Erythropoietin | 1 | 1997 | 144 | 0.040 |
Why?
|
Thrombocytopenia | 1 | 2004 | 1172 | 0.030 |
Why?
|
Mutation | 4 | 2010 | 29915 | 0.030 |
Why?
|
Sepsis | 1 | 2010 | 2587 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2019 | 819 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2024 | 1613 | 0.030 |
Why?
|
Polycythemia | 1 | 1997 | 125 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6493 | 0.030 |
Why?
|
Animals | 6 | 2015 | 167777 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 1997 | 388 | 0.030 |
Why?
|
Chlorambucil | 1 | 1994 | 42 | 0.030 |
Why?
|
Flow Cytometry | 3 | 2012 | 5864 | 0.030 |
Why?
|
Histiocytosis | 1 | 2014 | 40 | 0.030 |
Why?
|
Myelodysplastic Syndromes | 1 | 2004 | 1392 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2022 | 11152 | 0.030 |
Why?
|
Vitiligo | 1 | 2014 | 97 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2019 | 2218 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3298 | 0.030 |
Why?
|
Sequence Deletion | 1 | 1997 | 1492 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 2634 | 0.030 |
Why?
|
Granulocytes | 1 | 2014 | 550 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2009 | 18125 | 0.030 |
Why?
|
Dexamethasone | 1 | 2020 | 1927 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2001 | 6209 | 0.030 |
Why?
|
Cell Lineage | 1 | 2001 | 2533 | 0.030 |
Why?
|
Transplantation Chimera | 1 | 2014 | 595 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2019 | 1888 | 0.020 |
Why?
|
Central Nervous System | 1 | 2018 | 1333 | 0.020 |
Why?
|
Neck | 1 | 2016 | 731 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2008 | 7843 | 0.020 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2014 | 495 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1840 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1793 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3812 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2019 | 4809 | 0.020 |
Why?
|
Daunorubicin | 1 | 2010 | 156 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2013 | 424 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6293 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2001 | 3602 | 0.020 |
Why?
|
Head | 1 | 2016 | 921 | 0.020 |
Why?
|
Prognosis | 2 | 2024 | 29558 | 0.020 |
Why?
|
Aminoglycosides | 1 | 2010 | 163 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2010 | 270 | 0.020 |
Why?
|
Age Factors | 2 | 2019 | 18357 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3099 | 0.020 |
Why?
|
Young Adult | 4 | 2019 | 58808 | 0.020 |
Why?
|
Survival Rate | 2 | 2015 | 12721 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2014 | 830 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2014 | 1764 | 0.020 |
Why?
|
Histiocytosis, Sinus | 1 | 2008 | 46 | 0.020 |
Why?
|
Base Pairing | 1 | 2008 | 140 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 614 | 0.020 |
Why?
|
Antigens, CD1 | 1 | 2010 | 439 | 0.020 |
Why?
|
Pregnancy | 1 | 2009 | 29742 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5629 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2925 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2012 | 1256 | 0.020 |
Why?
|
Needs Assessment | 1 | 2013 | 1141 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3671 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2610 | 0.020 |
Why?
|
Heterozygote | 2 | 2008 | 2797 | 0.020 |
Why?
|
Autoimmunity | 1 | 2014 | 1358 | 0.020 |
Why?
|
DNA Mutational Analysis | 2 | 2010 | 4106 | 0.020 |
Why?
|
Psoriasis | 1 | 2014 | 938 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2022 | 6457 | 0.020 |
Why?
|
Social Class | 1 | 2015 | 1999 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2470 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2012 | 11070 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2010 | 1734 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4567 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2024 | 15773 | 0.020 |
Why?
|
Macrophage Activation | 1 | 2008 | 552 | 0.020 |
Why?
|
Erythroid Cells | 1 | 2006 | 235 | 0.010 |
Why?
|
Cytogenetics | 1 | 2004 | 198 | 0.010 |
Why?
|
Blotting, Southern | 1 | 2004 | 777 | 0.010 |
Why?
|
Cytokines | 1 | 2019 | 7338 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2001 | 11471 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6233 | 0.010 |
Why?
|
Blood Cell Count | 1 | 2004 | 395 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3806 | 0.010 |
Why?
|
Adult | 4 | 2024 | 219916 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1994 | 1627 | 0.010 |
Why?
|
Splenectomy | 1 | 2004 | 391 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6768 | 0.010 |
Why?
|
Gene Rearrangement | 1 | 2008 | 1122 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 2006 | 1751 | 0.010 |
Why?
|
Ultrasonography | 1 | 2016 | 5952 | 0.010 |
Why?
|
Clone Cells | 1 | 2006 | 1660 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2013 | 2768 | 0.010 |
Why?
|
Exons | 1 | 2008 | 2387 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7377 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 1994 | 4738 | 0.010 |
Why?
|
Homozygote | 1 | 2006 | 1788 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 2012 | 14641 | 0.010 |
Why?
|
Mice | 3 | 2006 | 81107 | 0.010 |
Why?
|
Cohort Studies | 2 | 2013 | 41252 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2004 | 1829 | 0.010 |
Why?
|
Survival Analysis | 1 | 2012 | 10112 | 0.010 |
Why?
|
Neutropenia | 1 | 2004 | 884 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10505 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13959 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1997 | 763 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3774 | 0.010 |
Why?
|
United States | 2 | 2015 | 72140 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2006 | 18942 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 12945 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6068 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6520 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15785 | 0.010 |
Why?
|
Genes, Dominant | 1 | 1997 | 862 | 0.010 |
Why?
|
Middle Aged | 2 | 2024 | 219560 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1997 | 1991 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2015 | 39060 | 0.010 |
Why?
|
Erythropoietin | 1 | 1997 | 719 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20500 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2014 | 15638 | 0.010 |
Why?
|
Genes, p53 | 1 | 1994 | 712 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8506 | 0.010 |
Why?
|
Risk Assessment | 1 | 2013 | 23883 | 0.010 |
Why?
|
Camptothecin | 1 | 1994 | 588 | 0.010 |
Why?
|
Proteomics | 1 | 2004 | 3816 | 0.010 |
Why?
|
Liver | 1 | 2006 | 7502 | 0.010 |
Why?
|
Pedigree | 1 | 1997 | 4578 | 0.010 |
Why?
|
Prospective Studies | 1 | 2013 | 54136 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 36285 | 0.000 |
Why?
|
Tumor Cells, Cultured | 1 | 1994 | 6127 | 0.000 |
Why?
|
Base Sequence | 1 | 1997 | 12436 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1997 | 13447 | 0.000 |
Why?
|
Cell Survival | 1 | 1994 | 5781 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1997 | 17617 | 0.000 |
Why?
|
Cell Line | 1 | 1997 | 15594 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1997 | 12760 | 0.000 |
Why?
|
Aged | 1 | 2004 | 168217 | 0.000 |
Why?
|